Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial-Reference-Cited by-同舟云学术

Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial

Published:2017-07-04 Issue:12 Volume:56 Page:1776-1785
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Malmström Annika¹²^ORCID,Poulsen Hans Skovgaard³,Grønberg Bjørn Henning⁴⁵^ORCID,Stragliotto Giuseppe⁶,Hansen Steinbjørn⁷,Asklund Thomas⁸,Holmlund Birgitta²⁹,Łysiak Małgorzata²,Dowsett Joseph¹⁰,Kristensen Bjarne Winther¹⁰,Söderkvist Peter²^ORCID,Rosell Johan²¹¹^ORCID,Henriksson Roger¹²,

Affiliation:

1. Department of Oncology, Linköping University Hospital, Linköping, Sweden;

2. Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden;

3. Department of Oncology, Dept. 5073, Rigshospitalet, København Ø, Denmark;

4. Department of Cancer Research and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway;

5. The Cancer Clinic, St. Olav’s Hospital – Trondheim University Hospital, Trondheim, Norway;

6. Department of Neurology, Karolinska University Hospital, Solna, Sweden;

7. Department of Oncology, Odense University Hospital, University of Southern Denmark, Odense, Denmark;

8. Department of Oncology, Radiumhemmet, Karolinska University Hospital, Solna, Sweden;

9. Department of Oncology, Linköping University, Linköping, Sweden;

10. Department of Pathology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, Odense C, Denmark;

11. Regional Cancer Center South East Sweden, Linköping, Sweden;